Market capitalization | $29.09m |
Enterprise Value | $34.94m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1,164.67 |
P/S ratio (TTM) P/S ratio | 969.67 |
P/B ratio (TTM) P/B ratio | 7.90 |
Revenue growth (TTM) Revenue growth | 2,557.10% |
Revenue (TTM) Revenue | $30.00k |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
4 Analysts have issued a Eyenovia, Inc. forecast:
4 Analysts have issued a Eyenovia, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.03 0.03 |
-
|
|
Gross Profit | -1.79 -1.79 |
106%
106%
|
|
EBITDA | -31 -31 |
37%
37%
|
EBIT (Operating Income) EBIT | -32 -32 |
37%
37%
|
Net Profit | -38 -38 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
Head office | United States |
CEO | Michael Rowe |
Employees | 57 |
Founded | 2014 |
Website | www.eyenovia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.